JAMA Network Open IF 10.5 Jul 24 2026 LoE II Full text read
Glucagon-Like Peptide-1 Receptor Agonists and Fragility Fracture Risk in Type 2 Diabetes
This retrospective study used US electronic health records to compare 66,803 propensity-matched pairs of adults with type 2 diabetes who started either a GLP-1 receptor agonist (like semaglutide or liraglutide) or a DPP-4 inhibitor. Over 3 years, patients starting a GLP-1 RA had a 21% lower relative risk of fragility fracture than those starting a DPP-4i (hazard ratio 0.79), with the largest protection seen for vertebral and hip fractures, and this benefit appeared independent of weight loss or blood sugar changes. However, the protective effect faded by year 3, and in a separate analysis GLP-1 RA use was actually associated with higher fracture risk in people without diabetes.
AI summary · from the full text
Why it mattersOrthopedic surgeons increasingly manage fragility fractures in an aging population on GLP-1 receptor agonists, and this large observational signal raises the question of whether these drugs affect bone health differently than assumed.
Rigor × clinical importance